Bayesian Capital Management’s GoodRx Holdings GDRX Stock Holding History

Bayesian Capital Management’s Portfolio GDRX Stock Details GDRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,900	Closed	-$69.2K	–	629
2025 Q2	$69.2K	Buy	+13,900	New	+$60.4K	0.01%	500
2024 Q2	–	Sell	-13,868	Closed	-$98.5K	–	879
2024 Q1	$98.5K	Sell	13,868 -27,100	-66%	-$179K	0.01%	714
2023 Q4	$274K	Sell	40,968 -14,400	-26%	-$81.1K	0.03%	534
2023 Q3	$312K	Buy	+55,368	New	+$369K	0.04%	464
2023 Q2	–	Sell	-70,139	Closed	-$438K	–	888
2023 Q1	$438K	Buy	70,139 +15,800	+29%	+$88.1K	0.05%	430
2022 Q4	$253K	Buy	+54,339	New	+$268K	0.04%	540
2021 Q3	–	Sell	-6,398	Closed	-$230K	–	444
2021 Q2	$230K	Buy	+6,398	New	+$236K	0.06%	341

Other funds holding GDRX

FPM

Francisco Partners Management San Francisco, California $292M AUM 34.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

SLG

Silver Lake Group Menlo Park, California $3.68B AUM 7.22% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Focus Partners Wealth Boston, Massachusetts $89.9B AUM 20.5% 1-Year Est. Return

PTC

Petrus Trust Company Dallas, Texas $915M AUM 2.95% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Bayesian Capital Management's GDRX Position: Q3 2025 in Review

Bayesian Capital Management sold out of GoodRx Holdings (GDRX) in Q3 2025, closing a stake of 13,900 shares — an estimated $69.2K sold.

Bayesian Capital Management first reported a position in GDRX in Q2 2021 and held it in 7 quarters. The position peaked at $438K in Q1 2023. 161 funds tracked by Wall St. Rank hold GDRX as of Q3 2025.

Bayesian Capital Management reported no remaining GoodRx Holdings position as of Q3 2025 after selling out during the quarter.
Bayesian Capital Management sold 13,900 GoodRx Holdings shares in Q3 2025, an estimated $69.2K.
Bayesian Capital Management first reported a position in GoodRx Holdings in Q2 2021 and held it in 7 quarters.
Bayesian Capital Management's GoodRx Holdings position peaked at $438K in Q1 2023.
161 funds tracked by Wall St. Rank held GoodRx Holdings as of Q3 2025.

Based on Bayesian Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.